US biosimilars consensus thwarted by three big issues
This article was originally published in SRA
Executive Summary
If US Food and Drug Administration officials had hoped a consensus would emerge when they invited stakeholders to participate in a two-day meeting on 2 and 3 November on how to create a pathway for follow-on biologics to get onto the US market, they were surely disappointed.